AsymBio, a biologics-focused Contract Development and Manufacturing Organisation (CDMO) has broken ground on the construction of its new R&D building at a Shanghai Fengxian site.
The project marks a pivotal infrastructure step in strengthening AsymBio’s biologics CDMO capabilities and reinforcing the Fengxian site’s role as a core development-and-manufacturing hub.
Fengxian R&D Building
Construction began in May 2026, with full completion and official commissioning slated for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land, provide nearly 20,000 square meters of gross floor area, and be constructed in full compliance with green and low-carbon construction standards.
The facility will support cell line development, upstream and downstream process development, conjugation process development, drug product development, and comprehensive analytical development services.
Located within AsymBio’s Fengxian site, adjacent to the clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the building will serve as a dedicated R&D hub.
Once operational, it will work in close alignment with the site’s production lines to streamline scale-up and commercial manufacturing while shortening overall project timelines.
The Fengxian R&D building will also provide the core physical carrier for the AccPCC (Accelerated PCC platform), an integrated R&D acceleration platform designed to shorten the development timeline from lead to preclinical candidate (PCC) selection. Built around an end-to-end, AI-enabled workflow, AccPCC connects early R&D and CMC with nonclinical evaluation and early clinical translation.
The platform delivers full-spectrum technical support spanning lead optimisation, developability assessment, and early-stage customised CMC strategy for global biotech partners.